HRMY Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
261.3M
+21.3%
215.4M
-11.6%
243.8M
+1.8%
239.5M
+19.4%
200.5M
Cost of Revenue
63.2M
+42.0%
44.5M
-35.1%
68.5M
+14.9%
59.6M
+56.3%
38.2M
Gross Profit
198.1M
+15.9%
170.9M
-2.5%
175.2M
-2.5%
179.8M
+10.8%
162.3M
Operating Expenses
108.8M
-18.6%
133.6M
-2.3%
136.7M
+19.6%
114.3M
+0.1%
114.2M
R&D
46.6M
-32.8%
69.4M
+39.0%
49.9M
-9.1%
55.0M
+9.6%
50.2M
SG&A
62.2M
-3.2%
64.2M
-26.0%
86.7M
+46.1%
59.4M
-7.3%
64.0M
Operating Income
89.3M
+139.5%
37.3M
-3.3%
38.6M
-41.1%
65.5M
+35.9%
48.2M
EBITDA
83.4M
+92.7%
43.3M
-5.9%
46.0M
-35.6%
71.5M
+69.2%
42.2M
Net Income
75.4M
+132.2%
32.5M
+44.5%
22.5M
-55.8%
50.9M
+27.9%
39.8M
EPS (Basic)
$1.30
+132.1%
$0.56
+43.6%
$0.39
-55.7%
$0.88
+27.5%
$0.69
EPS (Diluted)
$1.28
+132.7%
$0.55
+44.7%
$0.38
-56.3%
$0.87
+27.9%
$0.68
Shares (Diluted)
58.8M
-0.0%
58.8M
+0.5%
58.5M
-0.4%
58.7M
+0.5%
58.4M
Harmony Biosciences (HRMY) โ€” Financials